Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chao Teng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Chenshi Lin

    School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

    2 shared publications
  • Shenyu Chen

    Faculty of Medicine, The University of Queensland, Brisbane, Australia

    2 shared publications
  • Boran Li

    School of Business, China Pharmaceutical University, Nanjing 210009, China

    1 shared publication
  • Chao Qin

    Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China

    1 shared publication
  • Chaoyue Wang

    Department of Psychiatry, School of Mental Health, Wenzhou Medical University, Wenzhou, People’s Republic of China

    1 shared publication
  • Chenlu Xie

    Department of Pharmacy, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, China

    1 shared publication

Latest Publications

  • Open Access

    Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies

    by Yibin Cai, Jiayin Li, Shenyu Chen, Hui Zhang, Jie Tan, Hao Li, Shuyuan Zhang, Boran Li, Qin Wei, Chenshi Lin, et al.

  • Co-delivery of indomethacin and uricase as a new strategy for inflammatory diseases associated with high uric acid

    by Jie Liu, Chenshi Lin, Man Wu, Yingjie Wang, Shenyu Chen, Taiwang Yang, Chenlu Xie, Yue Kong, Wenliang Wu, Jiaping Wang, et al.

    Uric acid is the final metabolite in humans. High level of uric acid chronically induces urate deposition, aggravates kidney damage, and concomitantly causes an increase in inflammatory factors. Alleviating acute inflammation and decreasing uric acid levels are the key points in the treatment of inflammatory diseases associated with high uric acid. However, a drug delivery system that combines anti-inflammatory and uric acid reduction functions at the same time remains a challenge to be settled. Here, we designed a nanocrystal-based co-delivery platform, IND Nplex, characterized by loading of indomethacin (IND) and uricase. Compared with free IND or uricase, IND Nplex possessed a better anti-inflammatory effect by restraining the release of inflammation-related factors in vitro. In addition, pharmacokinetic and biodistribution studies revealed that IND Nplex significantly prolonged the retention time in vivo and was more concentrated in the kidney. In acute gouty arthritis model rats, IND Nplex markedly relieved ankle joint swelling and mitigated synovial inflammation. In acute kidney injury model rats, IND Nplex indicated better biocompatibility and significant amelioration of renal fibrosis. Moreover, IND Nplex showed the effect of anti-inflammatory and improved renal function via determination of inflammatory factors and biochemical markers in the serum and kidney. In conclusion, these results indicate that IND Nplex exerts anti-inflammatory activity and uric acid–lowering effect and could become a promising candidate for the treatment of uric acid–related diseases. Graphical Abstract In this study, a stable neutral co-delivery platform (IND Nplex) was fabricated by using a co-delivery strategy, allowing for a combination of the anti-inflammation drug IND and the metabolic enzyme uricase. IND Nplex showed a good therapeutic effect on rats with acute gouty arthritis or acute kidney injury due to the dual effects of anti-inflammatory and uric acid lowering. This platform provided a novel strategy for high uric acid–related illnesses.


  • Open Access

    Prevalence and Associated Factors of PTSD Symptoms After the COVID-19 Epidemic Outbreak in an Online Survey in China: The Age and Gender Differences Matter

    by Jiankai Mao, Chaoyue Wang, Chao Teng, Mengpu Wang, Siyao Zhou, Ke Zhao, Xiangming Ye, Yijia Wang

    Introduction: The COVID-19 is a highly contagious disease belonging to the family of coronaviruses which can affect a great deal of people shortly. As a devastating event in the world, many people suffer the PTSD from this severe disease. The aim of study is to explore the prevalence and severity of post-traumatic stress disorder (PTSD) symptoms, and discuss the possible factors among the general public in China after the COVID-19 epidemic outbreak. Methods: This is a cross-sectional study. We used the self-designed demographic questionnaire and the Posttraumatic Stress Checklist-Civilian Version (PCL-C) of Chinese version as our screening tools to investigate 4872 subjects living in the communities in China from Nov. 8th, 2020 to Dec. 8th, 2020. Results: Finally, we received 3705 effective respondents. The response rates of the questionnaire can reach 76.97 percentage. Peculiarly, the prevalence of PTSD mild and severe symptoms after the COVID-19 epidemic outbreak was 53.2%. Mild PTSD symptoms accounted for 24.9%, and severe PTSD symptoms (scores above 38) accounted for 28.3%. PCL-C mean scores were 41.4± 14.7. The females accounted for 67.7% of the total samples. Participants’ mean age was 30.5± 11.2 years old. The PCL-C gross scores of females were all higher than males in four subject groups. Meantime, gender and age made differences not only in total PCL-C points but also in the four aspects of PCL-C (P< 0.001). The middle-aged group (ages from 45 to 60) got the lowest scores among the four groups. Conclusion: COVID-19 brought tremendous psychological pressure on the public in many ways, including people’s work, social contact, study, and daily life. Results of our research discover that symptoms of the PTSD are severe, including the re-experiencing, avoidance/numbing, flashbacks, and hyper-arousal. Actions should be taken at society level to prevent and protect individuals from PTSD suffering. Special attention should be paid to females and young people. Further studies should be conducted to explore the dynamic and other risk and protection factors to prevent PTSD.